Wang X, et al. (2001) Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20, 4370-9 11500364

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S366-p - EEF2K (human) ▲

Modsite: sPQVRtLsGSRPPLL SwissProt Entrez-Gene Orthologous residues EEF2K (human): S366‑p, EEF2K (mouse): S365‑p, EEF2K (rat): S365‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial), ES (stem) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE p70S6K (human) KINASE p90RSK (human) KINASE P70S6KB (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE p90RSK (human) KINASE p70S6K (human) genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IGF-1 increase rapamycin IGF-1 inhibit treatment-induced increase LY294002 IGF-1 inhibit treatment-induced increase PD184352 IGF-1 no effect upon treatment-induced increase U0126 IGF-1 no effect upon treatment-induced increase phorbol_ester increase PD184352 phorbol_ester inhibit treatment-induced increase rapamycin phorbol_ester no effect upon treatment-induced increase